In September 2025, the World Health Organization added Semaglutide and Tirzepatide to its Model List of Essential Medicines — a quiet bureaucratic act with the potential to redirect the course of a slow-moving public health crisis. India, where the overweight and obese population has grown fourfold in a single generation to 235 million people, stands at a crossroads: the global machinery for making these drugs affordable has been set in motion, but whether that machinery will be engaged remains a matter of political will and institutional follow-through. The listing does not guarantee access,
The Economic Times
· Sep 10, 2025
· health
· 2 min read
High
Sourcing: Verified
WHO adds weight-loss drugs to essential medicines list, could slash prices in India
India's obesity crisis affects 235 million people with projections reaching 520 million, contributing to preventable disease burden and health inequity.
◉
Health & Medicine
8412 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Bias & Framing
⚖
Article presents WHO's decision favorably with emphasis on potential price reductions and health benefits, using supportive framing without significant counterarguments or concerns.
Bias Direction
center-left
Confidence
MED
Problem-solution framing that emphasizes access and affordability benefits while positioning WHO action as progressive public health measure. Uses statistics on obesity surge to justify urgency.
popular weight-loss drugs
significant decision
substantially reduce prices
urgent health challenges
underserved areas
expanding access and improving health outcomes
Pharmaceutical industry concerns about generic competition and profit margins
Potential safety or efficacy concerns with these drugs
Debate over whether obesity should be classified as essential medicine priority vs. other conditions
Cost-benefit analysis of WHO's decision
Views from Indian pharmaceutical manufacturers
Criticism of off-label use or market expansion concerns
Geopolitical Impact
🌎
WHO's inclusion of Semaglutide and Tirzepatide on Essential Medicines List could dramatically reduce obesity drug prices in India and 150+ countries, reshaping pharmaceutical access and generic competition dynamics.
Escalation Risk
low
Confidence
HIGH
India
South Asia
Low-income and middle-income countries (LMICs)
Sub-Saharan Africa
Southeast Asia
Shift toward WHO-led public health governance over pharmaceutical pricing; reduced leverage for branded drug manufacturers; increased bargaining power for generic manufacturers and developing nations; potential tension between patent holders and access advocates; strengthens India's position as generic drug hub.
Similar to WHO's 2002 inclusion of antiretroviral drugs on EML, which catalyzed generic competition and dramatically reduced HIV treatment costs in developing nations, enabling mass treatment programs.
Economic Lens
📈
WHO's inclusion of Semaglutide and Tirzepatide in Essential Medicines List could reduce weight-loss drug prices in India by 40-60%, expanding market access and triggering generic competition in a growing obesity treatment sector.
Market Signal
mixed
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare & Medical Services
Generic Drug Manufacturing
Health Insurance & Reimbursement
Public Health Systems
Indian consumers will benefit from significantly lower out-of-pocket costs for weight-loss medications (potentially 40-60% price reduction), improving affordability for 235 million overweight/obese individuals. However, pharmaceutical companies may face margin compression, potentially affecting R&D investment and drug availability timelines.
India's government will likely adopt WHO's EML recommendation, triggering price regulation through NPPA (National Pharmaceutical Pricing Authority), accelerating generic drug approvals, and expanding coverage under public health schemes (PMJAY, state insurance programs). This may prompt pharmaceutical lobbying and potential patent challenges.